Worth to remember by physicians when using nonsteroidal anti-inflammatory drug Review article
Article Sidebar
Published:
Sep 30, 2014
Keywords:
nonsteroidal anti-inflammatory drugs, rheumatoid arthritis, gastrointestinal risk, cardiovascular risk
Main Article Content
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medications for musculoskeletal conditions, including rheumatoid arthritis and other systemic connective tissue diseases. Both traditional NSAIDs and coxibs increase risk of gastrointestinal and cardiovascular adverse events. These dangers can be limited with proper risk assessment. The lowest dose of a short-acting NSAID for the shortest time required is recommended. In the patient with the increased cardiovascular risk naproxen should be always NSAID of the first choice.
Article Details
How to Cite
Rupiński , R. (2014). Worth to remember by physicians when using nonsteroidal anti-inflammatory drug. Medycyna Faktow (J EBM), 7(3(24), 54-58. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2354
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Wanders A., Heijde Dv, Landewé R. et al.: Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005; 52(6): 1756-1765.
2. Zhou Y., Boudreau D.M., Freedman A.N. et al.: Trends in the use of aspirin and nonsteroidal anty-inflammatory drugs in general population. Pharmacoepidemiol. Drug Saf. 2014; 23: 43-50.
3. ACR AD HOC Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs. Recommendations for Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs: An American College of Rheumatology White Paper. Arthritis Rheum. 2008; 59(8): 1058-1073.
4. Hochberg M.C., Altman R.D., April K.T. et al.: American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012; 64(4): 465-474.
5. Antman E.M., Bennett J.S., Daugherty A. et al.: Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115(12): 1634-1642.
6. Scheiman J.M., Hindley C.E.: Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin. Ther. 2010; 32: 667-677.
7. Święcicki A., Antonienko A.: The peculiarities of pathogenesis of NSAID-induced gastrointestinal injuries and current prevention strategies. Reumatologia 2014; 52(3): 155-159.
8. Wallace J.L., Denou E., Vong L. et al.: Proton pump inhibitors and low-dose aspirin markedly exacerbate NSAID-induced small intestinal injury: link to dysbiosis? Gastroenterology 2011; 140: 68-87.
9. Tielemans M.M., Eikendal T., Jansen J.B., van Oijen M.G.: Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf. 2010; 33(6): 443-453.
10. Lanza F.L., Chan F.K., Quigley E.M.; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol. 2009; 104(3): 728-738.
11. Lanza F.L., Chan F.K., Quigley E.M.: Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID related ulcer complications. Am. J. Gastroenterol. 2009; 104(3): 728-738.
12. Peters M.J.L., Symmons D.P.M., McCarey D. et al.: EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 2010; 69: 325-331.
13. Juni P., Nartey L., Reichenbach S. et al.: Risk of cardiovascular events and rofecoxib: a cumulative metaanalysis. Lancet 2004, 364: 2021-2029.
14. Garcia Rodriguez L.A., Tacconelli S., Patrignani P.: Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general populations. J. Am. Coll. Cardiol. 2008; 52: 1628-1636.
15. Crofford L.J.: Use of NSAIDs in treating patients with arthritis. Arthritis Research & Therapy 2013; 15(suppl. 3): S2.
16. Lindhardsen J., Gislason G.H., Jacobsen S. et al.: Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with arthritis: a nationwide cohort study. Ann. Rheum. Dis. 2014; 73: 1515-1521.
17. Atchison J.W., Herndon C.M., Rusie E.: Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety. J. Manag. Care Pharm. 2013; 19(suppl 9-a): S3-S19.
18. Zorvolex label information. Iroko Pharmaceuticals, LLC. October 2013.
2. Zhou Y., Boudreau D.M., Freedman A.N. et al.: Trends in the use of aspirin and nonsteroidal anty-inflammatory drugs in general population. Pharmacoepidemiol. Drug Saf. 2014; 23: 43-50.
3. ACR AD HOC Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs. Recommendations for Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs: An American College of Rheumatology White Paper. Arthritis Rheum. 2008; 59(8): 1058-1073.
4. Hochberg M.C., Altman R.D., April K.T. et al.: American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012; 64(4): 465-474.
5. Antman E.M., Bennett J.S., Daugherty A. et al.: Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115(12): 1634-1642.
6. Scheiman J.M., Hindley C.E.: Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin. Ther. 2010; 32: 667-677.
7. Święcicki A., Antonienko A.: The peculiarities of pathogenesis of NSAID-induced gastrointestinal injuries and current prevention strategies. Reumatologia 2014; 52(3): 155-159.
8. Wallace J.L., Denou E., Vong L. et al.: Proton pump inhibitors and low-dose aspirin markedly exacerbate NSAID-induced small intestinal injury: link to dysbiosis? Gastroenterology 2011; 140: 68-87.
9. Tielemans M.M., Eikendal T., Jansen J.B., van Oijen M.G.: Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf. 2010; 33(6): 443-453.
10. Lanza F.L., Chan F.K., Quigley E.M.; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol. 2009; 104(3): 728-738.
11. Lanza F.L., Chan F.K., Quigley E.M.: Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID related ulcer complications. Am. J. Gastroenterol. 2009; 104(3): 728-738.
12. Peters M.J.L., Symmons D.P.M., McCarey D. et al.: EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 2010; 69: 325-331.
13. Juni P., Nartey L., Reichenbach S. et al.: Risk of cardiovascular events and rofecoxib: a cumulative metaanalysis. Lancet 2004, 364: 2021-2029.
14. Garcia Rodriguez L.A., Tacconelli S., Patrignani P.: Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general populations. J. Am. Coll. Cardiol. 2008; 52: 1628-1636.
15. Crofford L.J.: Use of NSAIDs in treating patients with arthritis. Arthritis Research & Therapy 2013; 15(suppl. 3): S2.
16. Lindhardsen J., Gislason G.H., Jacobsen S. et al.: Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with arthritis: a nationwide cohort study. Ann. Rheum. Dis. 2014; 73: 1515-1521.
17. Atchison J.W., Herndon C.M., Rusie E.: Musculoskeletal Pain Management: Current Perspectives and Novel Strategies to Improve Safety. J. Manag. Care Pharm. 2013; 19(suppl 9-a): S3-S19.
18. Zorvolex label information. Iroko Pharmaceuticals, LLC. October 2013.